A rigorous randomized clinical trial of rizatriptan conducted by UCLA and Mayo Clinic researchers failed to outperform placebo in relieving the acute symptoms of vestibular migraine.
This article was originally published on MedicalXpress.com
Rizatriptan shows no advantage over placebo within first hour for vestibular migraine
You may also be interested in:
The Latest
Microneedling Services in Edmonton: Benefits, Treatment Cost, and How It Works
Microneedling is a revolutionary skincare treatment that has gained popularity in recent years due to its numerous benefits, including reducing the appearance of scars, wrinkles, and acne, and promoting collagen production. Edmonton, the bustling capital […]
The Latest
PetVet Dx Revolutionizes Wildlife Conservation with AI and Molecular Diagnostics to Combat Incurable CWD in Deer and Elk
Chronic wasting disease (CWD), a devastating prion illness that affects North American cervids like deer and elk, poses a grave threat to their well-being and conservation efforts. Furthermore, it presents a potential risk of human […]
The Latest
Setting Boundaries: Nurturing a Healthy Partnership
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
Read More:
-
A new study published in The Lancet Child & Adolescent Health suggests that parental or caregiver intuition may outperform some traditional early warning systems in [...]
-
Long COVID—symptoms that linger long after the initial viral infection—can affect people of every age, including children. But the lasting symptoms in an infant, toddler, [...]
-
Robert F. Kennedy Jr., the health and human services secretary in the United States, held a recent news conference and made uninformed comments on autism. [...]
